EMPHYMAB BIOTECH, MEDICAL THERAPIES FOR EMPHYSEMA
If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2013-04-05
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Office of the Vice Chancellor for Research
Abstract
Emphymab™ Biotech was formed to develop and commercialize medical therapies that address serious lung diseases. The founders are scientists and clinicians at Indiana University School of Medicine. Emphymab’s lead technology is based on a novel monoclonal antibody that inactivates a newly discovered pathway involved in lung diseases and, thereby, halts progressive loss of lung function associated with emphysema. This technology has the potential to address the huge unmet medical need of patients suffering from chronic obstructive pulmonary disease (COPD) with emphysema, which is the 3rd leading cause of death worldwide.
Description
poster abstract
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Johnstone, Brian, Matthias Claus, and Irina Petrache. (2013, April 5). EMPHYMAB BIOTECH, MEDICAL THERAPIES FOR EMPHYSEMA. Poster session presented at IUPUI Research Day 2013, Indianapolis, Indiana.
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Source
Alternative Title
Type
Presentation